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Abstract: Guidelines recommend that patients with COPD are stratiﬁ  ed arbitrarily by baseline 
severity (FEV1) to decide when to initiate combination treatment with a long-acting β2-agonist 
and an inhaled corticosteroid. Assessment of baseline FEV1 as a continuous variable may 
provide a more reliable prediction of treatment effects. Patients from a 1-year, parallel-group, 
randomized controlled trial comparing 50 μg salmeterol (Sal), 500 μg ﬂ  uticasone propionate 
(FP), the combination (Sal/FP) and placebo, (bid), were categorized post hoc into FEV1 <50% 
and FEV1 ≥50% predicted subgroups (n=949/513 respectively). Treatment effects on clinical 
outcomes – lung function, exacerbations, health status, diary card symptoms, and adverse 
events – were investigated. Treatment responses based on a pre-speciﬁ  ed analysis explored 
treatment differences by severity as a continuous variable. Lung function improved with ac-
tive treatment irrespective of FEV1; Sal/FP had greatest effect. This improvement appeared 
additive in milder disease; synergistic in severe disease. Active therapy signiﬁ  cantly reduced 
exacerbation rate in patients with FEV1 <50% predicted, not in milder disease. Health status 
and breathlessness improved with Sal/FP irrespective of baseline FEV1; adverse events were 
similar across subgroups. The spirometric response to Sal/FP varied with baseline FEV1, and 
clinical beneﬁ  ts were not restricted to patients with severe disease. These data have implications 
for COPD management decisions, suggesting that arbitrary stratiﬁ  cations of baseline severity 
are not necessarily indicative of treatment efﬁ  cacy and that the beneﬁ  ts of assessing baseline 
severity as a continuous variable should be assessed in future trials.
Keywords: chronic obstructive pulmonary disease, FEV1, inhaled corticosteroid, long-acting 
β2-agonist, subgroups
Introduction
Patients with COPD are characterized by a reduced FEV1 and a tendency to experi-
ence symptomatic exacerbations and health status impairment (Calverley and Walker 
2003). Not all of these problems are present to the same degree at all stages of the 
illness, with exacerbations that require treatment occurring more frequently as lung 
function deteriorates. Although there is a statistically signiﬁ  cant relationship between 
health status and the degree of FEV1 impairment, individual conﬁ  dence intervals for 
any particular percentage-predicted FEV1 are wide. 
There is now clear evidence that currently prescribed inhaled drugs, whether long-
acting β2-agonists (LABAs) or inhaled corticosteroids (ICS), alone or in combination, 
have beneﬁ  cial effects in stable COPD (Mahler et al 2002; Calverley et al 2003a, 2003b; 
Szafranski et al 2003). While guidelines recommend that combined use of these drugs 
be reserved for advanced patients (BTS 1997; American Thoracic Society/European 
Respiratory Society Task Force 2004; GOLD 2005), it is not clear whether such 
treatment is equally effective at all stages of disease severity. Furthermore, whether 
individual treatment outcomes, such as lung function, exacerbation rate, and health 
status, differ as FEV1 worsens is also uncertain. 
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The most frequently used method of classifying 
severity is to apply threshold values of FEV1. Several 
expert groups recommend the separation of disease based 
on a predicted FEV1 threshold level of 50% (BTS 1997; 
American Thoracic Society/European Respiratory Soci-
ety Task Force 2004; National Collaborating Centre for 
Chronic Conditions 2004; GOLD 2005). Such classiﬁ  -
cations are somewhat arbitrary and may not accurately 
represent clinical response at all points on the continuum 
of disease severity. Perhaps a less judgmental approach 
would be to treat FEV1 as a continuous variable and relate 
this to the subsequent treatment response. Given the differ-
ent drugs used in COPD therapy and the several different 
outcomes to be examined, a large number of patients are 
required to address these issues.
The Trial of Inhaled Steroids and Long-acting 
β2-Agonists (TRISTAN) was a one-year, double-blind, 
placebo-controlled study of patients with stable COPD 
(Calverley et al 2003b). Patients with a range of FEV1 
severities (25%–70% predicted) were randomized to 
receive either salmeterol (Sal) or fluticasone propion-
ate (FP) alone or in a fixed-dose combination or an 
identical placebo, all twice daily. The results showed 
that Sal/FP significantly improved pretreatment FEV1, 
health status, and daily symptoms after 12 months com-
pared with placebo or monotherapy alone. The effect of 
Sal/FP in reducing the rate of exacerbations compared 
with placebo was greater in patients with FEV1 <50% 
predicted than in those with FEV1 ≥50%. However, the 
relationship between baseline severity and outcomes 
in TRISTAN was not fully analyzed by the time of 
the publication. In addition, data on the trend of effect 
along a continuous FEV1 variable was outside the scope 
of the original publication, data that would be a useful 
addition to the clinical evidence base. 
In this new, exploratory analysis, we have used data from 
TRISTAN to test the hypothesis that the severity of airﬂ  ow 
obstruction, as reﬂ  ected by the pretreatment FEV1, is an im-
portant determinant of the subsequent change in the speciﬁ  ed 
outcomes of treatment. To do this, post hoc analyses of the 
TRISTAN population were conducted to provide new data, 
whereby patients were categorized according to the arbitrary 
FEV1 threshold, and the potential effect of treatment on a 
variety of clinical outcomes assessed. In addition, treatment 
responses were evaluated by a pre-speciﬁ  ed analysis, in 
which FEV1 was assessed as a continuous variable. It was 
anticipated that these approaches would clarify the validity 
of FEV1 in deﬁ  ning treatment response in COPD. 
Methods
Full details of the study methodology, patient selection, and 
outcomes for the intention-to-treat (ITT) analysis have been 
presented previously (Calverley et al 2003b).
Subjects
Brieﬂ  y, we recruited 1465 outpatients with COPD aged 
40–79 years who were current or ex-smokers with at least 
a 10-pack-year history, had an initial FEV1 between 25% 
and 70% predicted, and who showed limited bronchodila-
tor reversibility. All patients had a history of daily cough 
with sputum, reported previous exacerbations that required 
treatment, and fulﬁ  lled the diagnostic criteria for COPD both 
clinically and spirometrically, as deﬁ  ned elsewhere (BTS 
1997; GOLD 2005).
We obtained approval from local ethics committees at 
each participating site, and all patients provided written 
informed consent.
Experimental design
Patients entered a 2-week run-in period during which any 
patient using ICS or LABAs had these medicines discontin-
ued. The use of inhaled salbutamol as a relief medication, and 
regular treatment with anticholinergics, mucolytics, and/or 
theophylline was permitted throughout the study. Patients 
clinically stable at the end of the run-in were randomized to 
one of the following treatments inhaled from a dry powder 
Diskus device (GlaxoSmithKline Inc., Research Triangle 
Park, NC, USA), twice daily for the subsequent 52 weeks: a 
combination of 50 μg Sal and 500 μg FP, 50 μg Sal or 500 μg 
FP alone, or placebo.
Assessments
Patient evaluations were conducted at weeks 0, 2, 4, 8, 16, 
24, 32, 40, and 52. At each visit, spirometry was recorded 
before use of salbutamol or the morning study medication. 
The number of COPD exacerbations – deﬁ  ned as episodes of 
symptomatic worsening that had required medical treatment 
with antibiotics and/or oral corticosteroids or an emergency 
hospital visit – that occurred since the previous visit was 
also noted.
Health status was assessed by the St George’s Respira-
tory Questionnaire (SGRQ) (Jones et al 1992). Additionally, 
a daily diary record was kept to record the number of times 
relief medication was used each day and the number of 
times the patient woke from sleep. Symptoms were scored 
as: breathlessness, 0 (none) to 4 (breathless at rest); cough, 0 International Journal of COPD 2006:1(3) 211
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(none) to 3 (severe); and sputum production, 0 (no sputum) 
to 4 (dark yellow–green). Adverse events were noted at each 
clinic visit by recording spontaneously reported complaints 
from patients, by asking about potentially treatment-related 
problems and by speciﬁ  cally examining the throat for can-
didiasis and the forearm for spontaneous bruising. 
Statistical analysis
Data are expressed as means and 95% conﬁ  dence intervals 
unless otherwise stated. 
The analysis population and methods were deﬁ  ned and 
written in the trial Data Analysis Plan prior to the unblinding 
of the treatments for post-hoc analysis. Covariates used for 
analysis, where applicable, were age, sex, country, smoking 
status, baseline % predicted FEV1, and baseline value of 
the response. The study was not powered to detect interac-
tions, so in order to check for signiﬁ  cant interactions, it 
was more conservative to test at a lower signiﬁ  cance level. 
Therefore, the interactions between treatment and baseline 
were tested for statistical signiﬁ  cance at the 0.10 level in the 
ITT population. This testing was performed when analyz-
ing the primary efﬁ  cacy variable, clinic FEV1, prior to use 
of salbutamol, and the secondary efﬁ  cacy variable of the 
number of moderate and/or severe COPD exacerbations. 
For all pair-wise comparisons, the null hypothesis was that 
of no treatment effect.
Pre-bronchodilator FEV1 was analyzed using repeated 
measures analysis (Brown and Prescot 1999). Time was 
included as a categorical variable and an unstructured 
variance–covariance matrix was ﬁ  tted with SAS PROC 
MIXED software version 6.12. These methods were also 
used to analyze SGRQ.
The number of exacerbations was analyzed by a maxi-
mum likelihood Poisson regression with the amount of time a 
patient had received treatment as an offset variable. The time 
to ﬁ  rst exacerbation and time to withdrawal were analyzed 
using Cox’s proportional hazards model (Cox 1972).
For the use of rescue medication, the median data for 
weeks 1–52 were analyzed using the van Elteren extension 
to the Wilcoxon rank sum test (Lehmann 1975; van Elteren 
1960) and stratiﬁ  ed by smoking status, and the conﬁ  dence 
limits were calculated with the Hodges–Lehmann method 
(Hollander and Wolfe 1973).
Analyses by baseline severity were conducted for the 
following parameters: pre-bronchodilator FEV1, exacerbations, 
health status (using the SGRQ), and diary card symptoms.
Two approaches were used to assess the inﬂ  uence of 
FEV1 on treatment response. In the ﬁ  rst method, which was 
pre-speciﬁ  ed but not fully analyzed at the time of publica-
tion, a continuous variable for baseline % predicted pre-
bronchodilator FEV1 was included in parametric statistical 
analyses (eg, FEV1 or exacerbations). This type of analysis 
was pre-speciﬁ  ed in the study data analysis plan prior to 
unblinding for the major efﬁ  cacy variables as a check that 
the treatment effects held true for a wide range of severities. 
The interaction between baseline severity and treatment was 
investigated using a model including a baseline severity-
by-treatment interaction term, and predicted values were 
obtained from the model baseline % predicted FEV1 values 
of 33%, 44%, and 55% (these were the quartile values which 
had been pre-speciﬁ  ed in the data analysis plan and were es-
sentially arbitrary). For measures requiring non-parametric 
analysis, such as diary card symptoms, this approach was 
inappropriate.
In the second method, undertaken post hoc, the subjects 
were categorized into two groups: those with pre-bronchodi-
lator FEV1 <50% predicted at baseline and those with 50% 
or more. Where any parametric statistical analyses were per-
formed (eg, SGRQ [Jones et al 1992]), this factor of severity 
was included in the model, along with an interaction term for 
treatment-by-severity. This allowed for the possibility that 
the two severity groups had different treatment effects. The 
least squares means and treatment differences were produced 
from this model containing the interaction term. Where non-
parametric analyses were performed, the subgroups were 
analyzed separately.
Results
Demographics and baseline 
characteristics
The demographic and baseline characteristics according to 
baseline severity are given in Table 1. As anticipated, patients 
in the FEV1 <50% subgroup had worse health status, were 
more likely to use inhaled medication before randomization, 
and were less likely to be current smokers than those in the 
FEV1 ≥50% subgroup. However, the number of pack-years 
smoked and the degree of bronchodilator reversibility were 
comparable between the two populations.
Following randomization to treatment, more patients in 
the FEV1 <50% subgroup withdrew than in the FEV1 ≥50% 
subgroup (Figure 1). Moreover, fewer patients receiving 
combination treatment withdrew than those on placebo or 
individual components alone, irrespective of baseline FEV1 International Journal of COPD 2006:1(3) 212
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severity (Figure 1). The main reason for withdrawals across 
both subgroups and all treatment arms was the presence of 
adverse events, particularly exacerbations of COPD. 
Lung function 
The ICS and LABA combination produced the greatest 
improvements in lung function compared with placebo and 
individual components alone in both severity subgroups 
(all p<0.001; Table 2). This was particularly apparent in 
the FEV1 <50% subgroup, where the treatment effect was 
twice the sum of individual components (Table 2). Treat-
ment responses following monotherapy were less consistent. 
While Sal alone led to signiﬁ  cant improvements (p≤0.02) in 
both severity populations, FP was only signiﬁ  cantly effective 
(p<0.001) in patients with less severe disease.
Overall, no statistically signiﬁ  cant interaction (p=0.102) 
between baseline FEV1 and treatment response was observed, 
indicating that treatment effects between subgroups were 
comparable.
Similar effects were observed when FEV1 was analyzed as 
a continuous variable (Table 2). Patients who received com-
bination therapy showed larger improvements in lung func-
tion compared with those receiving placebo and individual 
components alone, irrespective of their baseline FEV1. This 
response was most evident at the 25% percentile, in patients 
with particularly low lung function (FEV1 33% predicted), 
where the treatment effect following Sal/FP combination ther-
apy was twice the sum of individual components (Table 2). 
In contrast, FP monotherapy produced progressively smaller 
changes in FEV1 as baseline FEV1 declined. Nonetheless, 
no signiﬁ  cant treatment interactions by severity were noted 
across the whole data set (p=0.147).
Exacerbations
In the post hoc subgroup analyses a higher proportion of 
patients experienced an exacerbation (60%) in the severe 
population (FEV1 <50% predicted) as compared with those 
in the FEV1 ≥50% predicted subgroup (44%). 
All active treatments reduced the number of exacerbations 
relative to placebo, with proportionately greater effects in 
those episodes requiring treatment with oral corticosteroids. 
With all treatments, reductions in exacerbation rates com-
pared with placebo were statistically signiﬁ  cant in subjects 
with more severe COPD (FEV1 <50% predicted), but not 
Table 1 Demographic and baseline characteristics by baseline 
FEV1 severity
    Total FEV1 <50%   FEV1 ≥50%
 population   predicted   predicted
 (n=1465)   (n=949)     (n=513) 
Male    1060  (72%)   714  (75%)   343  (67%) 
Age    63  (9)   64  (8)   62  (9) 
ICS at screen   630  (51%)   525  (55%)   226  (44%) 
LABAs at screen    506  (41%)   413  (44%)   178  (35%) 
Current smokers   746  (51%)   456  (48%)   288  (56%) 
Pack-years   43  (22)   43  (22)   41  (22) 
SGRQ total score   48.2  (16.3)   50.7  (15.8)   43.5  (16.3) 
Pre-bronchodilator 
FEV1 (L)   1.27  (0.48)   1.03  (0.31)   1.71  (0.40) 
Pre-bronchodilator 
FVC (L)   2.47  (0.79)   2.23  (0.71)   2.90  (0.76) 
% predicted FEV1   44.6  (13.9)   36.1  (8.1)   60.3  (6.9) 
% reversibility in 
predicted FEV1   3.8  (4.4)   4.0  (4.4)   3.5  (4.3) 
NOTES: Data are number (%) or mean (SD) unless otherwise indicated. Three 
patients have missing baseline FEV1, so are not included in either subgroup.
Abbreviations: FVC, forced vital capacity; ICS, inhaled corticosteroids; LABAs, 
long-acting  β2-agonists; SGRQ, St George’s Respiratory Questionnaire. 
Figure 1 Study withdrawals by baseline severity and therapy group.
Abbreviations: FP 500, ﬂ  uticasone propionate 500 μg; Sal 50, salmeterol 50 μg; Sal/FP 50/500, salmeterol/ﬂ  uticasone propionate 50/500 μg.
FEV1< 50% predicted FEV1 ≥ 50% predicted
(n = 949)
TRISTAN pivotal trial
(n = 1465)
(n = 513)
Placebo Placebo Sal Sal Sal/FP Sal/FP FP FP
(n = 239) (n = 244) (n = 235) (n = 231) (n = 122) (n = 127) (n = 139) (n = 125)
Completed
Withdrew
Completed
Withdrew
131 90
32 39 29 35
96 88 104
108
165 162 172
79 73 59International Journal of COPD 2006:1(3) 213
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signiﬁ  cant in those with FEV1 ≥50% predicted (Table 3). 
Exacerbation rates were consistently lower with combination 
therapy than with Sal or FP monotherapy in all subgroups, 
although these effects did not reach statistical signiﬁ  cance 
(Table 3). Moreover, no signiﬁ  cant treatment interactions by 
severity group for all exacerbations (p=0.410) or exacerba-
tions requiring oral corticosteroids (p=0.675) were noted.
Again, broadly similar results were seen when the esti-
mated annual rates of exacerbation were analyzed according 
to baseline severity as a continuous variable (Figure 2). As 
baseline FEV1 declined, more exacerbations occurred, al-
though there was no signiﬁ  cant treatment interaction by sever-
ity (p=0.139). All treatments signiﬁ  cantly reduced the rate of 
exacerbations at the arbitrary FEV1 44% and 33% predicted 
quartiles, but only Sal monotherapy produced a signiﬁ  cant 
reduction within the less severe 55% predicted quartile. 
With regard to comparisons between active treatments, the 
reduction in exacerbation rate seen with combination treat-
ment was signiﬁ  cantly greater than that seen with Sal alone 
at the FEV1 33% predicted quartile (p=0.043). However, 
no signiﬁ  cant differences were seen between combination 
treatment and FP alone.
There was a delay in the time to ﬁ  rst exacerbation with 
the active treatments compared with placebo in the more 
severe subgroup, this delay being particularly apparent in 
patients receiving combination treatment (median 109 days 
vs 47 days; p=0.003). The time to ﬁ  rst exacerbation was 
slightly longer in the less severe population with all active 
treatments compared with placebo, but this was not statisti-
cally signiﬁ  cant (Figure 3).
Health status and symptoms
The largest improvement in health status compared with 
placebo, indicated by a reduction in SGRQ score, occurred 
Table 2 Effect of 52 weeks’ treatment on pre-bronchodilator FEV1 according to baseline severity and therapy group
Analysis   Population    (n)   Placebo   Sal/FP   Sal   FP 
   (353)   (345)   (361)     (371)   
    FEV1 <50% predicted   
 Patients  (n)       234       226   238       233 
 Mean  baseline  FEV1(L)   1.02   1.03 1.03   1.03 
 Treatment  difference
a vs placebo
 (95% CI)    -    110 (75, 145)    42 (7, 76)    18 (–16, 53) 
  Treatment difference vs Sal/FP (95% CI)    -  -  69 (34, 103)  92 (57, 126)
  p-value vs placebo   -  <0.001        0.017     0.296 
  p-value vs Sal/FP   -       -   <0.001   <0.001 
 
  FEV1 ≥50% predicted   
 Patients  (n)       119       119   123       138 
 Mean  baseline  FEV1(L)   1.73   1.84       1.65   1.65 
  Treatment difference vs placebo
 (95% CI)    -  176 (128, 225)    96 (48, 143)    79 (33, 126) 
  Treatment difference vs Sal/FP (95% CI)    -  -  81 (33, 129)    97 (51, 144) 
  p-value vs placebo   -  <0.001  <0.001   <0.001 
  p-value vs Sal/FP   -       -   <0.001   <0.001 
 
  At 25th percentile (33% predicted)   
  Treatment difference vs placebo
 (95% CI)   -      113 (77, 149)       38 (2, 74)       18 (–18, 54) 
  Treatment difference vs Sal/FP (95% CI)    -  -  75 (39, 110)    94 (58, 130)
  p-value vs placebo   -  <0.001   0.037     0.316 
  p-value vs Sal/FP     -      -   <0.001   <0.001 
    At median (44% predicted)   
  Treatment difference vs placebo
 (95% CI)   -      132 (104, 160)       61 (33, 89)      40 (13, 67) 
  Treatment difference vs Sal/FP (95% CI)   -  -    71 (43, 99)    92 (64, 119) 
  p-value vs placebo   -  <0.001   <0.001   0.004 
  p-value vs Sal/FP   -      -     <0.001   <0.001   
    At 75th percentile (55% predicted)        
  Treatment difference vs placebo
 (95% CI)   -      151 (116, 186)       84 (49, 119)       62 (27, 96) 
  Treatment difference vs Sal/FP (95% CI)    -  -  67 (32, 102)    89 (55, 124)
  p-value vs placebo   -    <0.001   <0.001   <0.001 
  p-value vs Sal/FP       -     -   <0.001     <0.001 
aTreatment difference=mL. 
Abbreviations: FP, ﬂ  uticasone propionate; Sal, salmeterol; Sal/FP, salmeterol and ﬂ  uticasone propionate combination.
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in patients receiving combination therapy. There was no 
relationship between treatment effect on health status and 
baseline spirometry (p=0.598). The treatment effect compared 
with placebo reached statistical signiﬁ  cance only in patients 
with baseline FEV1 <50% who were treated with combina-
tion therapy (–2.3 units, 95% CI –3.7 to –0.8, p=0.002). In 
the less severe subgroup, there was a similar improvement 
in health status with combination therapy which, although 
not statistically signiﬁ  cant, approached signiﬁ  cance (–1.9 
units, 95% CI –3.9 to 0.1, p=0.058)  (Table 4). 
There were no consistent effects of baseline FEV1 sever-
ity on diary card symptom scores. Diary card data in both 
severity subgroups showed that patients receiving combi-
nation treatment were signiﬁ  cantly less likely to use relief 
medication than those who received placebo (p≤0.001), 
Sal alone (p<0.03), or FP alone (p≤0.004). Combination 
treatment was also more effective than placebo (p<0.004) 
in improving breathlessness in both subgroups, night-time 
awakenings in the more severe subgroup (p=0.029), and 
cough score in the less severe population (p=0.001). Overall, 
there was no clear evidence of treatment differences between 
the two severity subgroups.
Safety
All treatments were well tolerated. The frequency of adverse 
events was comparable between the severity subgroups 
(74%–81% and 67%–81%, across <50% and >50% sub-
groups, respectively). Morning serum cortisol concentrations 
were lower in patients who had received active treatment 
compared with those on placebo, and this was statistically 
Table 3 Effect of 52 weeks’ treatment on exacerbation rate according to baseline severity and therapy group
    Placebo   Sal/FP     Sal   FP
   All  exacerbations     
FEV1 <50% predicted   
Patients (n)
a       239       231       244       235 
Exacerbation rate based on Poisson model
b   1.42   0.99   1.09   1.07 
Treatment difference vs placebo (95% CI)
c    -
  30% (17, 41)    23% (9, 35)    24% (10, 36) 
Treatment difference vs Sal/FP (95% CI)
d    -  -  9% (–8, 24)    8% (–10, 22) 
p-value vs placebo   -  <  0.001   0.002   0.001 
p-value vs Sal/FP   -     -       0.266   0.378   
FEV1 ≥50% predicted   
Patients (n)       122       125       127   139 
Exacerbation rate based on Poisson model
b   1.09   0.98   0.98       1.05 
Treatment difference vs placebo (95% CI)
c    -
  10% (–22, 33)    10% (–21, 33)    3% (–29, 37) 
Treatment difference vs Sal/FP (95% CI)
d    -  -  –1% (–37, 26)    7% (–25, 30) 
p-value vs placebo   -  0.511  0.488  0.831 
p-value vs Sal/FP   -     -       0.975   0.633   
  Exacerbations requiring oral corticosteroids 
FEV1 <50% predicted   
Patients (n)       239       231       244       235 
Exacerbation rate based on Poisson model
b   0.81   0.47   0.58   0.52 
Treatment difference vs placebo (95% CI)
c    -
  43% (29, 54)    29% (13, 42)    35% (20, 48) 
Treatment difference vs Sal/FP (95% CI)
d   -  -    19% (–1, 35)    11% (–12, 29) 
p-value vs placebo   -  <0.001   <0.001   <0.001 
p-value vs Sal/FP   -       -   0.059   0.323 
FEV1 ≥50% predicted   
Patients (n)       122       127       139       125 
Exacerbation rate based on Poisson model
b   0.66   0.50   0.47   0.47 
Treatment difference vs placebo (95% CI)
c    -
  24% (–17, 51)    29% (–9, 54)    29% (–6, 53) 
Treatment difference vs Sal/FP (95% CI)
d    -  -  –7% (–68, 33)    –7% (–65, 31) 
p-value vs placebo   -  0.116  0.094   0.205 
p-value vs Sal/FP   -     -       0.785   0.759 
an=number of patients in the active groups. 
bExacerbation rate deﬁ  ned as the mean number of exacerbations per year from Poisson model. 
cTreatment difference represents the percentage reduction in exacerbation rate vs placebo. 
dTreatment difference represents the percentage change for Sal/FP vs individual components (negative value represents a reduction in exacerbations for component).
Abbreviations: FP, ﬂ  uticasone propionate; Sal/FP, salmeterol and ﬂ  uticasone propionate combination; Sal, salmeterol. International Journal of COPD 2006:1(3) 215
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signiﬁ  cant in patients (at 24 weeks) who had received Sal/FP 
(p=0.04) and FP (p=0.01; at 52 weeks). There was no increase 
in the incidence of bruise counts in either of the subgroups 
following active treatment compared with placebo, with 
more than 98% of patients in both subgroups and across 
treatments reporting no spontaneous bruising. The frequency 
of patients in both subgroups and across treatment groups 
who experienced hoarseness and cough, predictable side ef-
fects associated with ICS use, was found to be 1%–4% and 
1%–5%, respectively. 
Discussion
Although randomized controlled trials remain our primary 
source of evidence when choosing treatment, diseases like 
COPD where there is pathological heterogeneity among 
patients and concerns about the inﬂ  uence of disease sever-
ity on response to treatment, are well suited to a subgroup 
analysis of large data sets (Rothwell 2005). To be valid such 
an analysis should consider a limited number of subgroups, 
be pre-deﬁ  ned, and report comparisons primarily in terms 
of treatment by subgroup interaction as was the case in our 
study (Rothwell 2005). Current treatment recommendations 
in COPD use consensus-based thresholds of spirometric 
severity (BTS 1997; GOLD 2005) and subsequent studies 
have either reported subgroup analyses based on these (Jones 
et al 2003) or restricted recruitment of patients according to 
these criteria (Calverley et al 2003a; Szafranski et al 2003). 
Unsurprisingly in the light of previous data suggesting ICS 
treatment has a greater effect in more severe COPD (Burge 
et al 2000), subgroup analysis to identify potentially respon-
sive patients was requested by regulators following the ITT 
report of the TRISTAN data. In this new analysis, we found 
that most treatment effects could not be predicted reliably 
using an arbitrary split of baseline FEV1 <50% and ≥50%, 
although the effect of treatment on exacerbation frequency 
was most evident in those with worst initial lung function. 
Thus rigid adherence to speciﬁ  c thresholds may not be the 
best way to determine treatment in COPD, and we propose 
from this exploratory analysis that due consideration is given 
to deﬁ  ne more tightly which groups of patients are likely 
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to beneﬁ  t from combination treatment, whichever agents 
are used. 
While the TRISTAN trial was a relatively large study it 
was powered statistically only to show a difference between 
combination therapy and placebo treatment, making addition-
al comparisons between the combination and its individual 
components statistically less robust. For this reason we have 
reported the modeled data analysis which was pre-speciﬁ  ed 
but considered to be exploratory and hypothesis-generating 
in nature. It is important to note, however, that not all of the 
clinical outcomes were suited to this approach – for example, 
rescue medication was not; in this case, analysis based on 
categorization by the threshold approach was employed.
The spirometric changes with therapy were small, as 
would be expected in patients already selected for their 
limited bronchodilator reversibility. However, such changes 
are a reproducible marker of the effect of treatment on lung 
function and are a qualitative indicator of the likely effect 
of treatment on more complex physiological outcomes 
(O’Donnell et al 1999).
 Subgroup analysis revealed that 
treatment improved lung function irrespective of baseline 
FEV1, with the largest changes observed when the bron-
chodilator Sal and the ICS FP were combined. On analyzing 
treatment responses based on FEV1 as either a categorical 
or continuous variable, in patients with less severe disease, 
the use of combination treatment improved FEV1 to a degree 
equivalent to the sum of the individual components. As se-
verity of disease increased and baseline FEV1 declined, the 
addition of the ICS to Sal appeared to be more than simply 
additive. These data may explain why combining treatment 
is relatively more effective in patients with the worst initial 
lung function.
The relationship seen between exacerbation rate and base-
line lung function was in keeping with other studies (Jones 
et al 2003; Szafranski et al 2003). The lower exacerbation 
rate in patients with an FEV1 ≥50% predicted following 
combination therapy was not statistically different from 
that observed with placebo, although when analyzing FEV1 
as a continuous variable, Sal alone appeared to be effective 
in this less severe population. However, it should be noted 
that despite the entry criteria, there were substantially fewer 
exacerbations than expected, with 46% of the total popula-
tion not experiencing an exacerbation during the study. This 
signiﬁ  cantly reduced the power of the study to detect differ-
ences, as the smaller number of patients in the FEV1 ≥50% 
subgroup reduced the potential for the analysis to identify a 
statistically signiﬁ  cant effect.
Even in the more severe subgroup, the exacerbation 
rate in the placebo arm (1.4 per patient per year) was 
lower than that seen in apparently similar patients receiving 
placebo in other 1-year studies (1.8–1.9 events per year) 
(Szafranski et al 2003; Calverley et al 2003a). This may 
reﬂ  ect differences in patient recruitment between centers 
and the effect of increased patient supervision in reducing 
medical contacts due to the repeated clinic visits (Bourbeau 
et al 2003). Nonetheless, if the number of patients with an 
Table 4 Effect of 52 weeks’ treatment on SGRQ total score according to baseline severity and therapy group
Severity subgroup   Placebo   Sal/FP     Sal     FP   
FEV1 <50% predicted   
Patients (n)       211       205       212       219 
Mean baseline SGRQ   49.8   50.2   51.3   51.1 
Adjusted mean change in SGRQ   –1.3   –3.6   –2.6   –1.7 
Treatment difference vs placebo
 (95% CI)
a    -  –2.3 (–3.7, –0.8)    –1.3 (–2.8, 0.1)    –0.5 (–1.9, 1.0) 
Treatment difference vs Sal/FP (95% CI)
b    -  -  –0.9 (–2.4, 0.5)    –1.8 (–3.2, –0.4) 
p-value vs placebo   -  0.002   0.069   0.527 
p-value vs Sal/FP     -     -   0.201     0.014 
FEV1 ≥50% predicted   
Patients (n)       107       115       108       121 
Mean baseline SGRQ   41.0   41.3   43.0   47.4 
Adjusted mean change in SGRQ   –2.1   –4.0   –2.7   –3.5 
Treatment difference vs placebo
 (95% CI)
a    -  –1.9 (–3.9, 0.1)    –0.6 (–2.6, 1.4)    –1.4 (–3.3, 0.6) 
Treatment difference vs Sal/FP (95% CI)
b    -  -  –1.3 (–3.3, 0.7)    –0.6 (–2.5, 1.4)
p-value vs placebo   -  0.058   0.544     0.175 
p-value vs Sal/FP   -     -     0.199     0.572 
aTreatment difference – a negative value indicates superiority of active group (improvement in SGRQ). 
bTreatment difference – a negative value indicates superiority of Sal/FP over individual components.
(A clinically relevant reduction in SGRQ total score is a decline of at least 4 points.)
Abbreviations: FP, ﬂ  uticasone propionate; Sal/FP, salmeterol and ﬂ  uticasone propionate combination; Sal, salmeterol; SGRQ, St George’s Respiratory Questionnaire.International Journal of COPD 2006:1(3) 217
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FEV1 <50% predicted who need to be treated to prevent one 
exacerbation (NNT) is calculated, then the NNT is 2.4 per 
year of therapy if combination and placebo are compared 
using the observed exacerbation rate in the placebo group. 
If the exacerbation rate is used from the year prior to study 
entry (two exacerbations per patient), the NNT is 1.7 per year. 
Even if combination therapy is compared with Sal using the 
observed exacerbation rates, the NNT is 10 per year. These 
numbers are well within the range considered beneﬁ  cial in 
most clinical specialties.
The relationship between health status and FEV1 is 
much weaker than that between health status and exacerba-
tions (Spencer et al 2004). This may explain why the health 
status effects seen in this study were unrelated to the initial 
spirometry, with a similar ranking order of effect between 
monotherapy and combination treatment in both severe and 
milder patients. Methodological factors might have reduced 
the power of the present study to show a clinically signiﬁ  cant 
difference but there is no suggestion that baseline lung 
function would predict such a change.
Breathlessness (as measured by the Transitional Dyspnoea 
Index [Mahler et al 1984]) has been shown to improve with 
combination treatment but was not speciﬁ  cally assessed 
here (Mahler et al 2002). The changes in the daily diary card 
would be compatible with such an effect but there was no 
evidence that initial lung function predicted beneﬁ  t in most 
of the symptoms, where this was reported. Encouragingly, 
there was no evidence of any worse adverse event proﬁ  le in 
relation to baseline lung function.
COPD management guidelines try to offer balanced 
advice about the relative efﬁ  cacy and hazards of current 
treatment, often having to use limited evidence to shape their 
recommendations. Their proposal to introduce ICS therapy 
in those with an FEV1 <50% predicted is a reasonable one 
given the uncertainties about the longer-term safety of ICS 
in COPD, a point which may be resolved when prospective 
mortality data become available from studies such as TORCH 
(Vestbo 2004). However, this should not be confused with 
treatment having no effect in patients above this arbitrary 
threshold value. As our subgroup analyses demonstrated, all 
the therapies were effective, irrespective of the initial FEV1, 
with Sal/FP producing the greatest beneﬁ  t in a number of 
outcomes. These data support the approach outlined in the 
UK NICE recommendations (NICE 2004), where treatment is 
offered according to the presence of symptoms rather than at 
a speciﬁ  c FEV1 value and may provide preliminary evidence 
for revision of baseline severity stratiﬁ  cations within current 
guidelines. While accepting the limitations of this study, this 
preliminary evidence may provide the basis for considering 
a revision of baseline severity stratiﬁ  cations within current 
guidelines. Thus, the potential beneﬁ  ts of assessing baseline 
severity as a continuous variable and the impact this may have 
on management decisions should be studied and validated in 
future, large clinical studies.
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